Juvenile myasthenia gravis

From diagnosis to treatment

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction at the postsynaptic motor end plate, resulting in damage to the structure or function of the acetylcholine receptors. Juvenile myasthenia gravis presents with fluctuating muscle weakness and fatigue before the age of 19 years. These symptoms can affect the oculomotor musculature, bulbar system or have a generalized involvement. The diagnosis is similar to that in adults, made using electrophysiological techniques and antibody testing. Treatment is divided into medical and surgical. The medical management is oriented towards acetylcholinesterase inhibitors, immunosuppression and immunomodulation, including the use of steroids, intravenous immunoglobulin and plasmapheresis. Steroid sparing agents can be used with caution in refractory cases. Surgical approach is based on thymectomy. Future research, ideally prospective randomized controlled data, is needed to understand the differences between the adult and pediatric population, efficacy of therapies and outcomes.

Original languageEnglish (US)
Title of host publicationNovel Challenges in Myasthenia Gravis
PublisherNova Science Publishers, Inc.
Pages207-221
Number of pages15
ISBN (Print)9781634830003, 9781634829779
StatePublished - Jul 1 2015

Fingerprint

Myasthenia Gravis
Neuromuscular Junction Diseases
Steroids
Motor Endplate
Thymectomy
Muscle Fatigue
Plasmapheresis
Immunomodulation
Intravenous Immunoglobulins
Cholinesterase Inhibitors
Muscle Weakness
Cholinergic Receptors
Immunosuppression
Pediatrics
Antibodies
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Castro, D. (2015). Juvenile myasthenia gravis: From diagnosis to treatment. In Novel Challenges in Myasthenia Gravis (pp. 207-221). Nova Science Publishers, Inc..

Juvenile myasthenia gravis : From diagnosis to treatment. / Castro, Diana.

Novel Challenges in Myasthenia Gravis. Nova Science Publishers, Inc., 2015. p. 207-221.

Research output: Chapter in Book/Report/Conference proceedingChapter

Castro, D 2015, Juvenile myasthenia gravis: From diagnosis to treatment. in Novel Challenges in Myasthenia Gravis. Nova Science Publishers, Inc., pp. 207-221.
Castro D. Juvenile myasthenia gravis: From diagnosis to treatment. In Novel Challenges in Myasthenia Gravis. Nova Science Publishers, Inc. 2015. p. 207-221
Castro, Diana. / Juvenile myasthenia gravis : From diagnosis to treatment. Novel Challenges in Myasthenia Gravis. Nova Science Publishers, Inc., 2015. pp. 207-221
@inbook{6c9387676bac48d0935cb283be0e8223,
title = "Juvenile myasthenia gravis: From diagnosis to treatment",
abstract = "Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction at the postsynaptic motor end plate, resulting in damage to the structure or function of the acetylcholine receptors. Juvenile myasthenia gravis presents with fluctuating muscle weakness and fatigue before the age of 19 years. These symptoms can affect the oculomotor musculature, bulbar system or have a generalized involvement. The diagnosis is similar to that in adults, made using electrophysiological techniques and antibody testing. Treatment is divided into medical and surgical. The medical management is oriented towards acetylcholinesterase inhibitors, immunosuppression and immunomodulation, including the use of steroids, intravenous immunoglobulin and plasmapheresis. Steroid sparing agents can be used with caution in refractory cases. Surgical approach is based on thymectomy. Future research, ideally prospective randomized controlled data, is needed to understand the differences between the adult and pediatric population, efficacy of therapies and outcomes.",
author = "Diana Castro",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
isbn = "9781634830003",
pages = "207--221",
booktitle = "Novel Challenges in Myasthenia Gravis",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Juvenile myasthenia gravis

T2 - From diagnosis to treatment

AU - Castro, Diana

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction at the postsynaptic motor end plate, resulting in damage to the structure or function of the acetylcholine receptors. Juvenile myasthenia gravis presents with fluctuating muscle weakness and fatigue before the age of 19 years. These symptoms can affect the oculomotor musculature, bulbar system or have a generalized involvement. The diagnosis is similar to that in adults, made using electrophysiological techniques and antibody testing. Treatment is divided into medical and surgical. The medical management is oriented towards acetylcholinesterase inhibitors, immunosuppression and immunomodulation, including the use of steroids, intravenous immunoglobulin and plasmapheresis. Steroid sparing agents can be used with caution in refractory cases. Surgical approach is based on thymectomy. Future research, ideally prospective randomized controlled data, is needed to understand the differences between the adult and pediatric population, efficacy of therapies and outcomes.

AB - Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction at the postsynaptic motor end plate, resulting in damage to the structure or function of the acetylcholine receptors. Juvenile myasthenia gravis presents with fluctuating muscle weakness and fatigue before the age of 19 years. These symptoms can affect the oculomotor musculature, bulbar system or have a generalized involvement. The diagnosis is similar to that in adults, made using electrophysiological techniques and antibody testing. Treatment is divided into medical and surgical. The medical management is oriented towards acetylcholinesterase inhibitors, immunosuppression and immunomodulation, including the use of steroids, intravenous immunoglobulin and plasmapheresis. Steroid sparing agents can be used with caution in refractory cases. Surgical approach is based on thymectomy. Future research, ideally prospective randomized controlled data, is needed to understand the differences between the adult and pediatric population, efficacy of therapies and outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84957008910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957008910&partnerID=8YFLogxK

M3 - Chapter

SN - 9781634830003

SN - 9781634829779

SP - 207

EP - 221

BT - Novel Challenges in Myasthenia Gravis

PB - Nova Science Publishers, Inc.

ER -